Clinical Trials Logo

Leriche Syndrome clinical trials

View clinical trials related to Leriche Syndrome.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06349382 Not yet recruiting - Clinical trials for Abdominal Aortic Aneurysm

CArbohydrate Loading in Aortic Surgery

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

The adverse effects of overnight fasting before surgery have been well-documented in the contemporary literature. Still, due to the possibility of pulmonary aspiration of gastric contents, many clinicians worldwide still employ this practice. On the other hand, the benefits of preoperative oral carbohydrate loading (OCHL) have been shown in various patient groups. Studies examining the usefulness of preoperative OCHL in aortic surgery are lacking. In particular, no randomized control trials have specifically examined the impact of preoperative OCHL on the postoperative course in patients undergoing open abdominal aortic surgery.

NCT ID: NCT06260475 Not yet recruiting - Clinical trials for Peripheral Arterial Disease

IUA Committee Research Project on the Management of TASC C and D Aortoiliac Lesions

Start date: March 1, 2024
Phase:
Study type: Observational

This study aims to evaluate the clinical, imaging results of endovascular revascularization of the aorto-iliac sector in comparison with aortobifemoral bypass and the hybrid approach, in patients with atherosclerotic disease of the iliac sector classified as type C and D by the TransAtlantic Inter-Society Consensus (TASC II

NCT ID: NCT06253312 Not yet recruiting - Clinical trials for Peripheral Arterial Disease

Treatment of TASC C and D Aortoiliac Lesions

Start date: May 1, 2024
Phase:
Study type: Observational

Background: The treatment of patients with complex aortoiliac disease (AID), classified as Trans-Atlantic Inter-Society consensus II (TASC) class C and D, presents a dilemma for vascular surgeons. Current guidelines recommend either open surgical reconstruction (OR), hybrid repair (HR) combining iliac stenting with femoral endarterectomy, or total endovascular repair (ER). While traditional OR with aortobifemoral bypass (ABF) is associated with excellent long term patency results, it is associated with significant perioperative morbidity with some studies citing mortality rates of up to 4-8%. The advancement of endovascular techniques has led to many trials suggesting that endovascular management of TASC II C and D lesions is a potential alternative treatment to open strategies mainly in the subset of patients with high surgical risk, given the substantially less perioperative morbidity and mortality compared to OR. Aim: The aim of this trial is to evaluate the short, mid-, and long-term results of open repair, hybrid and endovascular repair in the treatment patients with complex, TASC C and D, aortoiliac lesions. Methodology: This is a retrospective cohort study planning to include vascular surgery centers from the following countries: Italy, Portugal, Spain, and Serbia. Data will be collected on demographics, baseline comorbidities, anatomy and morphology of the aortoiliac and femoral bifurcation disease, intraoperative, postoperative, and follow-up data. Propensity score analysis will be performed by matching open repair patients in all three groups (open, hybrid, and endovascular repair) controlling for demographics, baseline comorbidities, anatomical and morphological data. Endpoints: Primary endpoints are all-cause mortality and the major adverse limb events (major amputation - below and above the knee, new onset acute limb ischaemia, reintervention of the treated arterial segment). The secondary endpoints are the 30-day complications and primary patency.

NCT ID: NCT04148456 Not yet recruiting - Clinical trials for Aortoiliac Occlusive Disease

CERAB Technique for Aortoiliac Occlusive Disease

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

To evaluate the safety and efficacy of the CERAB technique as an alternative to surgical reconstruction for treatment of aorto-iliac occlusive disease.